

Succeeding in the 2020 UK Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

https://marketpublishers.com/r/SB90928489BEN.html

Date: February 2020 Pages: 565 Price: US\$ 4,500.00 (Single User License) ID: SB90928489BEN

Abstracts

LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant



market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests—Over 200 current and emerging assays including:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Market Segmentation Analysis

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products



Review of over 200 current and emerging cancer diagnostic tests, including: Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.



Contains 565 pages and 85 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

- 1. Market Overview
- 2. Worldwide Market Structure
- 3. Worldwide Market Size and Growth

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- **D.** Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology

Succeeding in the 2020 UK Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Comp...



- 1. Breast Cancer
- 2. Lung Cancer
- 3. Colon and Rectum Cancer
- 4. Prostate Cancer
- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

- 1. Introduction
- 2. Tumor Marker Classification
- 3. ACTH
- 4. Alpha-Fetoprotein (AFP)
- 5. Beta-2 Microglobulin
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. Calcitonin
- 10. Carcinoembrionic Antigen (CEA)
- 11. Estrogen and Progesterone Receptors
- 12. Ferritin
- 13. Gastrin
- 14. Human Chorionic Gonadotropin (HCG)
- 15. Insulin
- 16. NSE
- 17. Occult Blood
- 18. PAP Smear/HPV
- 19. Prostatic Acid Phosphatase (PAP)
- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers



27. Oncogenes Abl/abl-bcr AIB1 BCL-2 BRCA1 CD44 C-fos C-myb C-myc **CYP-17** Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src 28. Polypeptide Growth Factors **Basic Fibroblast Growth Factor** Beta-TGF Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) Ornithine Decarboxylase Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines Alpha-Interferon **B** Cell Growth Factors

B Cell Growth Factor (BCGF)



Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers N-Acetylglucosamine Actin Alpha-Actin Antineuronal Antibodies 7B2 B 72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA **CU18 DR-70** DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15



Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen HPA HSP27 **Intermediate Filaments** Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein** Neurofilaments Vimentin KA Kinases **KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin **NEA-130** NMP22 OA-519 **Opioid Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki-67



Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin **TA-90** TABA Tachykinin TAG TPS Troponin Tubulin **VCAM** VEGF Villen

C. Cancer Diagnostic Testing Instrumentation Review and Market Needs

- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - 3. Molecular Diagnostics
 - 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. Artificial Intelligence
 - 6. Flow Cytometry
 - 7. Two Dimensional Gel Electrophoresis (2-DGE)
 - 8. Biosensors
 - 9. Competing/Complementing Technologies
- E. Personal Testing



VIII. UK CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure

D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

IX. COMPETITIVE PROFILES

Abbott AdnaGen/Alere **Agilent Technologies** Applied Gene Technologies Arca Biopharma Beckman Coulter/Danaher **Becton Dickinson Biomedical Diagnostics** bioMerieux **Bio-Rad** CellSearch Cepheid Correlogic Systems/Vermillion **Decode Genetics** Diadexus Diagnocure Diasorin **Eiken Chemical** Elitech Group Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio **Guided Therapeutics** Hologic/Gen-Probe Kreatech/Leica Kyowa Medex Mackay Life Sciences



Myriad Genetics OncoLab **Ortho-Clinical Diagnostics** Panacea Pharmaceuticals Polartechnics Polymedco PreMD Qiagen **Quest Diagnostics Radient Pharmaceuticals** Roche Scienion Sequenom **Siemens Healthcare** Takara Bio **Targeted Diagnostics & Therapeutics** Tosoh Thermo Veridex Wako Pure Chemicals Wallac/PE Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS



List Of Tables

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast by Market Segment U.K., Estimated Cancer Death Rates Per 100,000 Population U.K., Laboratories Performing Tumor Marker Tests by Market Segment U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume



U.K., Total Tumor Marker Testing Volume Forecast by Market Segment

U.K., All Market Segments Major Tumor Marker Test Volume Forecast

U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test

U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast

U.K., Total Tumor Marker Sales Forecast by Market Segment

U.K., All Market Segments Major Tumor Marker Sales Forecast by Test

U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test

U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test

U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment

U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment



U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and Market Shares Forecast

U.K., CEA Testing Market Diagnostics Sales by Major Supplier

U.K., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: Succeeding in the 2020 UK Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

Product link: https://marketpublishers.com/r/SB90928489BEN.html

Price: US\$ 4,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/SB90928489BEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970